Skip to main content

Table 3 Variables associated with SVR12 in univariate and multivariate analysis

From: Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort

  n with SVR 12 / Total (%): Yes VS Reference Univariate Multivariate
OR (95% CI) p-Value OR (95% CI) p-Value
Ribavirin containing regimen (reference: no RBV) 60/63 (95) VS 495/536 (92) 1.66 (0.5–8.61) 0.5936   
Treatment duration 24 weeks (reference: 12 weeks) 62/69 (90) VS 493/530 (93) 0.67 (0.28–1.85) 0.4654   
Cirrhosis (reference: no cirrhosis) 304/335 (91) VS 244/257 (95) 0.52 (0.25–1.06) 0.0734 1.07 (0.36–3.20) 1.0000
Conjugated bilirubin ≥5 μmol/L (reference: <  5 μmol/L) 163/182 (90) VS 141/148 (95) 0.43 (0.15–1.1) 0,0835 0.58 (0.19–1.67) 0.3701
TP ≤ 70% (reference: >  70%) 59/68 (87) VS 458/491 (93) 0.47 (0.21–1.18) 0.1103 0.41 (0.14–1.22) 0.1148
Hemoglobin ≤12 g/dL for women or ≤ 13 g/dL for men(reference: > 12 g/dL or > 13 g/dL) 63/72 (88) VS 480/514 (93) 0.5 (0.22–1.23) 0.1338 0.59 (0.22–1.71) 0.3620
Platelets < 100,000/mm3 (reference: ≥ 100,000/mm3) 108/121 (89) VS 429/458 (94) 0.56 (0.27–1.22) 0.1505 1.12 (0.39–3.38) 1.0000
Genotype 1b (reference: 1 not subtyped or 1a or 4) 280/297 (94) VS 275/302 (91) 1.62 (0.83–3.24) 0.1757 0.94 (0.39–2.26) 1.0000
Male (reference: Female) 303/322 (94) VS 252/277 (91) 1.18 (0.65–2.13) 0.6504 1.62 (0.68–3.94) 0.3192
Genotype 1a (reference: 1 not subtyped or 1b or 4) 127/141 (90) VS 428/458 (93) 0.64 (0.32–1.34) 0.2489   
Neutrophil < 1500/mm3 (reference: ≥ 1500/mm3) 33/38 (87) VS 503/540 (93) 0.49 (0.17–1.69) 0.2641   
Chronic hepatitis duration ≥15 years (reference: <  15 years) 308/337 (91) VS 236/251 (94) 0.68 (0.33–1.34) 0.2980   
Albumin < 30 g/L (reference: ≥ 30 g/L) 16/19 (84) VS 479/519 (92) 0.45 (0.12–2.49) 0.3756   
Age > 65 years (reference: ≤ 65 years) 209/223 (94) VS 346/376 (92) 1.29 (0.65–2.7) 0.5478   
MELD ≥15 (reference: <  15) 31/35 (89) VS 454/491 (92) 0.63 (0.21–2.6) 0.5732   
Genotype 4 (reference: 1a or 1b or 1 not subtyped) 121/132 (92) VS 434/467 (93) 0.84 (0.4–1.89) 0.7409   
Viral load < 6 M at beginning of treatment (reference: ≥ 6 M) 502/542 (93) VS 42/44 (95) 0.6 (0.07–2.45) 0.7425   
ALAT > 5 ULN (reference: ≤ 5ULN) 33/35 (94) VS 511/551 (93) 1.29 (0.31–11.5) 0.9999   
ASAT > 5 ULN (reference: ≤ 5ULN) 34/37 (92) VS 508/547 (93) 0.87 (0.26–4.63) 0.9999   
Decompensated cirrhosis (reference: no decompensated cirrhosis) 22/24 (92) VS 533/575 (93) 0.87 (0.2–7.86) 0.9999   
Treatment experienced (reference: treatment naïve) 160/173 (92) VS 395/426 (93) 0.97 (0.48–2.07) 0.9999   
Genotype 1 not subtyped (reference: 1a or 1b or 4) 27/29 (93) VS 528/570 (93) 1.07 (0.25–9.63) 0.9999   
Previous treatment: PEG/RBV (reference: 1st generation PI/PEG/RBV or none) 365/394 (93) VS 190/205 (93) 0.99 (0.48–1.97) 0.9999   
  1. SVR Sustain virological response, RBV Ribavirin, PEG Pegylated interferon, PI Protease inhibitor